For our R&D development, we are looking for investors (capital contribution) sharing our values and vision.

You can see our R&D programs here. Our next development is the ChimioFx’s clinical validation during 2 years with 3 Hospitals. The goal is to confirm the sensibility, the sensitivity and the robustness of the test before his commercialization in 2021.

Looking for investment opportunities in a company with significant potential and high expertise in new innovative technologies associated to precision medicine assays? Don’t hesitate to contact us for more information.